Wealthfront Advisers LLC Cuts Holdings in CVS Health Corporation $CVS

Wealthfront Advisers LLC lowered its stake in shares of CVS Health Corporation (NYSE:CVS) by 3.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 187,884 shares of the pharmacy operator’s stock after selling 7,610 shares during the quarter. Wealthfront Advisers LLC’s holdings in CVS Health were worth $14,165,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in CVS. SOA Wealth Advisors LLC. raised its position in shares of CVS Health by 36.9% in the 3rd quarter. SOA Wealth Advisors LLC. now owns 486 shares of the pharmacy operator’s stock valued at $37,000 after purchasing an additional 131 shares during the last quarter. Symmetry Partners LLC increased its position in shares of CVS Health by 2.5% in the third quarter. Symmetry Partners LLC now owns 5,826 shares of the pharmacy operator’s stock valued at $439,000 after buying an additional 141 shares in the last quarter. Harbor Capital Advisors Inc. grew its position in shares of CVS Health by 72.1% in the third quarter. Harbor Capital Advisors Inc. now owns 339 shares of the pharmacy operator’s stock valued at $26,000 after purchasing an additional 142 shares during the period. HF Advisory Group LLC lifted its position in shares of CVS Health by 2.9% in the third quarter. HF Advisory Group LLC now owns 5,219 shares of the pharmacy operator’s stock valued at $393,000 after acquiring an additional 145 shares in the last quarter. Finally, United Asset Strategies Inc. raised its position in shares of CVS Health by 1.8% in the third quarter. United Asset Strategies Inc. now owns 8,852 shares of the pharmacy operator’s stock valued at $667,000 after buying an additional 154 shares during the last quarter. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

CVS Health Price Performance

NYSE:CVS opened at $75.54 on Wednesday. The firm has a market cap of $95.89 billion, a price-to-earnings ratio of 198.79, a price-to-earnings-growth ratio of 0.70 and a beta of 0.50. The company’s 50-day moving average is $78.52 and its two-hundred day moving average is $75.98. CVS Health Corporation has a 12-month low of $54.06 and a 12-month high of $85.15. The company has a current ratio of 0.83, a quick ratio of 0.63 and a debt-to-equity ratio of 0.83.

CVS Health (NYSE:CVS) last released its earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.09. The firm had revenue of $105.69 billion for the quarter, compared to the consensus estimate of $103.67 billion. CVS Health had a return on equity of 11.45% and a net margin of 0.12%.The firm’s revenue for the quarter was up 8.2% compared to the same quarter last year. During the same period in the prior year, the business posted $1.19 earnings per share. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. Research analysts expect that CVS Health Corporation will post 5.89 EPS for the current year.

CVS Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Thursday, January 22nd were given a $0.665 dividend. The ex-dividend date of this dividend was Thursday, January 22nd. This represents a $2.66 annualized dividend and a dividend yield of 3.5%. CVS Health’s dividend payout ratio is presently 700.00%.

Analysts Set New Price Targets

Several research analysts have recently weighed in on CVS shares. Truist Financial set a $100.00 price target on shares of CVS Health in a research report on Wednesday, December 10th. Weiss Ratings reiterated a “hold (c-)” rating on shares of CVS Health in a report on Monday, December 29th. Robert W. Baird lifted their price target on CVS Health from $82.00 to $92.00 and gave the stock an “outperform” rating in a report on Wednesday, December 10th. Argus dropped their price objective on CVS Health from $91.00 to $90.00 and set a “buy” rating on the stock in a report on Wednesday, January 28th. Finally, Wall Street Zen downgraded shares of CVS Health from a “buy” rating to a “hold” rating in a research note on Saturday, November 1st. Nineteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $94.82.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Q4 beat on revenue and adjusted EPS — revenue rose to $105.7B (+8.2%) and adjusted EPS beat consensus ($1.09). The results reflect strength in pharmacy/PBM volume that helps near‑term earnings. CVS Health beats quarterly profit expectations on pharmacy performance
• Positive Sentiment: Operational progress & record top line — full‑year 2025 revenue was a record ~$402.1B; CVS completed the transition to cost‑based pharmacy reimbursement and reported improvements in Aetna prior‑authorization times — positives for margin recovery and execution. CVS HEALTH CORPORATION REPORTS FOURTH QUARTER AND FULL-YEAR 2025 RESULTS
• Positive Sentiment: Wall‑street/TV commentary supportive — some market commentators (including Jim Cramer) highlighted catalysts around the turnaround and CEO execution, which can sustain investor interest despite near‑term noise. Jim Cramer on CVS: “I Think It’s a Fascinating Time to Own the Stock”
• Neutral Sentiment: Management reaffirmed multi‑year turnaround targets and emphasized the cost‑based pharmacy model — these are constructive for longer‑term margins but leave short‑term sensitivity to reimbursement and utilization. CVS Health reaffirms $7–$7.20 EPS target for 2026 while advancing cost-based pharmacy model
• Negative Sentiment: FY‑2026 EPS guidance came in below consensus — the company gave a $5.94–$6.14 EPS range that is materially lower than many Street forecasts, a key reason investors sold off after the print. CVS Beats on Q4 Earnings and Revenues but Shares Slide in Pre-Market
• Negative Sentiment: Medicare / MA rate worries — management called a 2027 Medicare Advantage rate notice “disappointing,” saying rates don’t match utilization trends; that raises downside risk to the insurer segment and long‑term margin assumptions. CVS Health CEO Joyner says ‘disappointing’ 2027 MA rate notice fails to match utilization trends
• Negative Sentiment: Cash‑flow and profit headwinds noted — some coverage flagged lowered cash‑flow guidance and that full‑year profit metrics missed certain expectations, which compounds investor concern despite the revenue beat. CVS Health beats Q4 expectations, cash flow guidance lowered CVS Health 2025 profit falls short of $1.8B

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.